Meridian Reports 1 Percent Drop in Q1 Revenues; Mixed Results in Dx, Life Science Segments | GenomeWeb

NEW YORK (GenomeWeb News) — Meridian Bioscience today reported a 1 percent year-over-year drop in fiscal 2014 first-quarter revenues with mixed results in both its Illumigene molecular diagnostics and core life science businesses.

For the three months ended Dec. 31, Meridian reported revenues of $44.8 million, compared to $45.4 million in the year-ago period and well short of the consensus analyst estimate of $49 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.